The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
The serotonin syndrome and its treatment
Abstract
Serotonin syndrome is caused by drug induced excess of intrasynaptic 5-hydroxytryptamine. The clinical manifestations are mediated by the action of 5-hydroxytryptamine on various subtypes of serotonin receptors. There is no effective drug treatment established. The history of the treatment of serotonin syndrome with 5-hydroxytryptamine blocking drugs is reviewed. A literature search was undertaken using both Medline and a manual search of the older literature. Reports of cases treated with the 5-HT 2 blockers cyproheptadine and chlorpromazine were identified and analysed. There is some evidence suggesting the efficacy of chlorpromazine and cyproheptadine in the treatment of serotonin syndrome. The evidence for cyproheptadine is less substantial, perhaps because the dose of cyproheptadine necessary to ensure blockade of brain 5-HT 2 receptors is 20–30 mg, which is higher than that used in the cases reported to date (4–16 mg).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,342
Neuroleptic malignant syndrome
Caroff, S. N., & Mann, S. C. (1993) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30278-4 · Cited by 514
Green, A. R., Cross, A. J., & Goodwin, G. M. (1995) · Psychopharmacology · doi:10.1007/bf02246288 · Cited by 415
Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.
Richelson, E., & Nelson, A. (1984) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21446-x · Cited by 341
A prospective analysis of 24 episodes of neuroleptic malignant syndrome
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.6.717 · Cited by 292
Selective Serotonin Reuptake Inhibitor-Induced Serotonin Syndrome: Review
Lane, R., & Baldwin, D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199706000-00012 · Cited by 247
PHARMACOLOGICAL STUDIES WITH THE SEROTONIN PRECURSOR, 5-HYDROXYTRYPTOPHAN
Bogdanski, D. F., Weissbach, H., & Udenfriend, S. (1958) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11954-x · Cited by 214
The Serotonin Syndrome: Implicated Drugs, Pathophysiology and Management
Sporer, K. A. (1995) · Drug Safety · doi:10.2165/00002018-199513020-00004 · Cited by 197
Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor
Oates, J. A., & Sjoerdsma, A. (1960) · Neurology · doi:10.1212/wnl.10.12.1076 · Cited by 189
Neuroleptic malignant syndrome. Review of response to therapy
Rosenberg, M. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.9.1927 · Cited by 185
Cited by
Depression in Late Life: Review and Commentary
Blazer, D. G. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.3.m249 · Cited by 2,344
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
Dunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H., & Whyte, I. M. (2003) · QJM · doi:10.1093/qjmed/hcg109 · Cited by 1,029
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Moses-Kolko, E. L., Bogen, D., Perel, J., Bregar, A., Uhl, K., Levin, B., & Wisner, K. L. (2005) · JAMA · doi:10.1001/jama.293.19.2372 · Cited by 533
Metadata
- Authors
- Gillman, P. K.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1999-01
- Volume
- 13
- Issue
- 1
- Pages
- 100-109
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2124712827
- Cited by
- 306
- References
- 73
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The serotonin syndrome and its treatment. https://app.cochat.ai/papers/10.1177/026988119901300111
- The paper
- Gillman, P. K. (1999). The serotonin syndrome and its treatment. Journal of Psychopharmacology. https://doi.org/10.1177/026988119901300111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.